Direct drug screening against the mammalian stage of Leishmania has been hampered by cost and the time consuming effort required to accomplish it. The ability to derive transgenic Leishmania expressing reporter genes opened up new possibilities for the development of drug screening tests. Further developments to standardize and gather multiple informations could now be envisionned. We will discuss on such available methodologies that could improve sensitivity, reliability, versatility and the rapidity, of the screen based on intracellular model. © 2006 Monte-Alegre et al; licensee BioMed Central Ltd.
Monte-Alegre, A., Ouaissi, A., & Sereno, D. (2006). Leishmania amastigotes as targets for drug screening. Kinetoplastid Biology and Disease, 5. https://doi.org/10.1186/1475-9292-5-6